Guselkumab

VANCOUVER, British Columbia — In a Healio video exclusive, Jan Wehkamp, MD, PhD, discusses results from the QUASAR study, in which Tremfya outperformed placebo in clinical response at weeks 12 and 24 among patients with ulcerative colitis.

In a Healio video exclusive, Jan Wehkamp, MD, PhD, reports that treatment with Tremfya maintained clinical remission and endoscopic response through 3 years among patients with moderate to severe Crohn’s disease.

M. Elaine Husni, MD, MPH, spoke with Healio about treatment and management options in psoriatic arthritis, including lifestyle changes. “We now have really embraced the concept of wellness strategies,” said Husni, vice chair of rheumatology and director of the Arthritis and Musculoskeletal Center and staff physician in the Orthopedic and Rheumatologic Institute at Cleveland Clinic, and assistant professor at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

CHICAGO — In a Healio video exclusive, Jessica R. Allegretti, MD, MPH, explains that nearly 23% of patients with moderate to severe ulcerative colitis achieved clinical remission with Tremfya, compared with less than 10% on placebo.

Long-term use of guselkumab in the treatment of psoriasis does not yield increased cancer rates compared with the general and psoriasis populations, according to a study.

Tremfya demonstrated greater treatment persistence than interleukin-17 inhibitors in patients with moderate to severe plaque psoriasis and achieved clinical efficacy in scalp psoriasis, according to data presented here.

The 2-year safety profile of guselkumab appears consistently favorable across patients with psoriatic arthritis who are either naïve or experienced with TNF inhibitors, according to data published by The Journal of Rheumatology.

WAILEA, Hawaii — Patients with psoriatic arthritis treated with guselkumab for 6 months experienced a significant improvement in joint disease, skin disease and pain, according to a poster presented at the Maui Derm meeting.

DENVER — Early data suggest combination therapy with biologics or advanced small-molecules may be safe and effective in patients with inflammatory bowel disease, according to a presenter at the Crohn’s and Colitis Congress.

CHARLOTTE, N.C. — Guselkumab in combination with golimumab induced greater rates of clinical remission compared with monotherapy among patients with moderate to severely active ulcerative colitis.